Nothing Special   »   [go: up one dir, main page]

HUP0300923A2 - RAF és RAS protein kinázt tartalmazó készítmények és alkalmazásuk angiogenezis módosítására - Google Patents

RAF és RAS protein kinázt tartalmazó készítmények és alkalmazásuk angiogenezis módosítására

Info

Publication number
HUP0300923A2
HUP0300923A2 HU0300923A HUP0300923A HUP0300923A2 HU P0300923 A2 HUP0300923 A2 HU P0300923A2 HU 0300923 A HU0300923 A HU 0300923A HU P0300923 A HUP0300923 A HU P0300923A HU P0300923 A2 HUP0300923 A2 HU P0300923A2
Authority
HU
Hungary
Prior art keywords
angiogenesis
raf
modulation
ras
protein kinase
Prior art date
Application number
HU0300923A
Other languages
English (en)
Inventor
David A. Cheresh
Brian Eliceiri
John Hood
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Publication of HUP0300923A2 publication Critical patent/HUP0300923A2/hu
Publication of HUP0300923A3 publication Critical patent/HUP0300923A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány szövetek angiogenezisének módosítására szolgáló, Raf vagyRas protein kinázt vagy ezek változatait tartalmazó készítményekrevonatkozik. A találmány olyan eljárásokra is kiterjed, amelyek azangiogenezis módosítására, azaz stimulálására vagy gátlásárairányulnak. A találmány szerinti készítmények az angiogenezistmódosító mennyiségben Raf és/vagy Ras proteint, vagy Raf és/vagy Rasprotein hatékony mennyiségét expresszálni képes nukleotid szekvenciáttartalmaznak valamely gyógyászatilag alkalmas hordozóanyaggal vagykötőanyaggal együtt. Az angiogenezis módosítása hasznos gyógymódotjelent számos betegség, többek között a rák kezelésében. Ó
HU0300923A 1999-08-13 2000-08-11 Methods and compositions useful for modulation of angiogenesis using protein kinase raf and ras HUP0300923A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14892499P 1999-08-13 1999-08-13
US21595100P 2000-07-05 2000-07-05
PCT/US2000/021842 WO2001012210A1 (en) 1999-08-13 2000-08-11 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase raf and ras

Publications (2)

Publication Number Publication Date
HUP0300923A2 true HUP0300923A2 (hu) 2003-07-28
HUP0300923A3 HUP0300923A3 (en) 2005-12-28

Family

ID=26846311

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300923A HUP0300923A3 (en) 1999-08-13 2000-08-11 Methods and compositions useful for modulation of angiogenesis using protein kinase raf and ras

Country Status (17)

Country Link
US (1) US20060040853A1 (hu)
EP (1) EP1210099A4 (hu)
JP (1) JP2003507337A (hu)
KR (2) KR100805098B1 (hu)
CN (1) CN1208087C (hu)
AU (1) AU781877B2 (hu)
BR (1) BR0013228A (hu)
CA (1) CA2380966A1 (hu)
CZ (1) CZ2002449A3 (hu)
HK (1) HK1050856A1 (hu)
HU (1) HUP0300923A3 (hu)
MX (1) MXPA02001553A (hu)
NO (1) NO20020718L (hu)
PL (1) PL364928A1 (hu)
RU (1) RU2257911C2 (hu)
SK (1) SK2142002A3 (hu)
WO (1) WO2001012210A1 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002223571A1 (en) * 2000-09-29 2002-04-08 Gsf-Forschungszentrum Fur Umwelt Und Gesundheit, Gmbh Pharmaceutical compositions comprising polynucleotides encoding a raf protein
RU2498983C2 (ru) * 2007-03-12 2013-11-20 Юм Биосайнсес Аустралия Пти Лтд Соединения фениламинопиримидина и их применения
MX2010007669A (es) 2008-01-14 2010-08-04 Genentech Inc Metodos para inhibir la angiogenesis utilizando antagonistas de egfl8.
EP2329854A3 (de) * 2009-12-04 2014-02-19 Biotronik VI Patent AG Implantatbeschichtung mit Nukleinsäuren
CN102766601B (zh) * 2011-11-17 2015-12-16 中山大学肿瘤防治中心 含有可诱导型癌基因的细胞系及其建立方法、应用
EP3151666B1 (en) * 2014-06-03 2019-11-20 Arturo Solis Herrera Animal models of corneal angiogenesis and corneal ectatic diseases, methods of producing, and methods of use thereof
RU2728870C2 (ru) * 2017-10-12 2020-07-31 Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) Полипептиды для лечения онкологических заболеваний
US20230218710A1 (en) * 2020-04-15 2023-07-13 Cohbar, Inc. Method of treating coronavirus infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618670A (en) * 1988-08-26 1997-04-08 The United States Of America As Represented By The Department Of Health & Human Services Detection method for c-raf-1 genes
US5156841A (en) * 1988-08-26 1992-10-20 United States Of America Anti-tumor vaccine
US5656612A (en) 1994-05-31 1997-08-12 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5597719A (en) 1994-07-14 1997-01-28 Onyx Pharmaceuticals, Inc. Interaction of RAF-1 and 14-3-3 proteins
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
AU5587998A (en) * 1996-11-15 1998-06-03 Cornell Research Foundation Inc. Activated ras interaction assay
US6376471B1 (en) * 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods

Also Published As

Publication number Publication date
BR0013228A (pt) 2003-06-17
KR100759241B1 (ko) 2007-09-18
EP1210099A4 (en) 2006-01-18
CZ2002449A3 (cs) 2002-08-14
KR100805098B1 (ko) 2008-02-20
SK2142002A3 (en) 2002-07-02
WO2001012210A1 (en) 2001-02-22
US20060040853A1 (en) 2006-02-23
HK1050856A1 (en) 2003-07-11
WO2001012210A9 (en) 2002-09-12
RU2257911C2 (ru) 2005-08-10
EP1210099A1 (en) 2002-06-05
KR20020032553A (ko) 2002-05-03
AU6763300A (en) 2001-03-13
NO20020718L (no) 2002-04-10
CN1378457A (zh) 2002-11-06
HUP0300923A3 (en) 2005-12-28
KR20070067210A (ko) 2007-06-27
CA2380966A1 (en) 2001-02-22
MXPA02001553A (es) 2003-05-23
AU781877B2 (en) 2005-06-16
JP2003507337A (ja) 2003-02-25
PL364928A1 (en) 2004-12-27
CN1208087C (zh) 2005-06-29
NO20020718D0 (no) 2002-02-12

Similar Documents

Publication Publication Date Title
DE69738754D1 (de) Hemmer der interaktion zwischen p53 und mdm2
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
DE60028970D1 (de) An her2 bindende peptidverbindungen
TR200201442T2 (tr) Ağrı hafifletme, kemik kanseri terapisi ve kemik yüzeyinin sağlıklı tutulması için kireçlenmiş hedef dokulara yönelik radyum-223 hazırlanması ve kullanımı.
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
TR201903587T4 (tr) Telomeraz aktivitesinin artırılması için bileşimler.
HK1042479A1 (en) 2-Amino-6-anilino-purines and their use as medicaments.
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
DE10085007T1 (de) Antiinfektionszusammensetzungen zur Behandlung von erkranktem Gewebe, wie Lippenherpes
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
ES2154354T3 (es) Ligandos tie-2, metodos para obtenerlos y sus usos.
WO2003042661A3 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
DK1992695T3 (da) Lectin-transmembran-antigen af type C udtrykt i human prostatacancer og avendelser deraf
ATE249220T1 (de) Verwendung von piperin und derivate davon zur behandlung von hautpigmentierungstörungen und hautkrebs
WO2002064088A3 (en) Pharmaceutical composition for the treatment of alopecia
DE602004016950D1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
SE0102147D0 (sv) New methods
WO2003017939A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
HUP0300923A2 (hu) RAF és RAS protein kinázt tartalmazó készítmények és alkalmazásuk angiogenezis módosítására
HUT64569A (en) A process for preparing polypeptide-type compounds usefules for medical treatment of the human body
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
MXPA02005069A (es) Agentes de enlace especificos para t3 y metodos para su uso.
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
WO2001010382A3 (en) Compositions and methods related to claudin-7

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees